Hepatitis C Articles (HCV)
Back
	GS-9857 in Genotypes 1-6       EASL: Preclinical Profile of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 - (04/29/15)   EASL: Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C - (04/24/15)   EASL: SAFETY AND EFFICACY OF SHORT-DURATION TREATMENT WITH GS-9857 COMBINED WITH SOFOSBUVIR/GS-5816 IN TREATMENT-NAIVE AND DAA-EXPERIENCED GENOTYPE 1 PATIENTS WITH AND WITHOUT CIRRHOSIS - (04/23/15)   EASL: Evaluation of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 in Healthy Volunteers - (04/29/15)           View Older Articles   Back to Top   www.natap.org